GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Instil Bio Inc (NAS:TIL) » Definitions » ROC (Joel Greenblatt) %

Instil Bio (Instil Bio) ROC (Joel Greenblatt) % : -30.69% (As of Dec. 2023)


View and export this data going back to 2021. Start your Free Trial

What is Instil Bio ROC (Joel Greenblatt) %?

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits). He defines ROC (Joel Greenblatt) % as EBIT divided by the total of Property, Plant and Equipment and net working capital. Instil Bio's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was -30.69%.

The historical rank and industry rank for Instil Bio's ROC (Joel Greenblatt) % or its related term are showing as below:

TIL' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -3465.79   Med: -134.83   Max: -85.73
Current: -87.21

During the past 5 years, Instil Bio's highest ROC (Joel Greenblatt) % was -85.73%. The lowest was -3465.79%. And the median was -134.83%.

TIL's ROC (Joel Greenblatt) % is ranked better than
68.78% of 1470 companies
in the Biotechnology industry
Industry Median: -339.53 vs TIL: -87.21

Instil Bio's 5-Year average Growth Rate of ROC (Joel Greenblatt) % was 0.00% per year.


Instil Bio ROC (Joel Greenblatt) % Historical Data

The historical data trend for Instil Bio's ROC (Joel Greenblatt) % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Instil Bio ROC (Joel Greenblatt) % Chart

Instil Bio Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
ROC (Joel Greenblatt) %
-3,465.79 -121.17 -176.78 -134.83 -85.73

Instil Bio Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
ROC (Joel Greenblatt) % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -105.41 -114.94 -39.03 -158.79 -30.69

Competitive Comparison of Instil Bio's ROC (Joel Greenblatt) %

For the Biotechnology subindustry, Instil Bio's ROC (Joel Greenblatt) %, along with its competitors' market caps and ROC (Joel Greenblatt) % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Instil Bio's ROC (Joel Greenblatt) % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Instil Bio's ROC (Joel Greenblatt) % distribution charts can be found below:

* The bar in red indicates where Instil Bio's ROC (Joel Greenblatt) % falls into.



Instil Bio ROC (Joel Greenblatt) % Calculation

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits) . He defines Return on Capital as follows:

ROC (Joel Greenblatt) %=EBIT/Average of (Net fixed Assets + Net Working Capital)

EBIT stands for Earnings Before Interest and Taxes.

Fixed Assets are also known as non-current assets. They include the Property, Plant and Equipment that the firm needs in its operation.

GuruFocus calculates net working capital as: (Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Deferred Revenue + Other Current Liabilities). We're trying to account for OPERATING assets and liabilities (part of daily business) when calculating working capital. Cash and marketable securities are considered NON-OPERATING assets and are not included in calculation. We will also back out all interest bearing debt, short term debt and the portion of long term debt that is due in the current period from the current liabilities. This debt will be considered when computing cost of capital and it would be inappropriate to count it twice.

Working Capital(Q: Sep. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 12.182) - (8.053 + 0 + 3.618)
=0.51099999999999

Working Capital(Q: Dec. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 10.403) - (7.593 + 0 + 1.216)
=1.594

When net working capital is negative, 0 is used.

So ROC (Joel Greenblatt) % of Instil Bio for the quarter that ended in Dec. 2023 can be restated as:

ROC (Joel Greenblatt) %(Q: Dec. 2023 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Sep. 2023  Q: Dec. 2023
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-43.78/( ( (142.107 + max(0.51099999999999, 0)) + (141.071 + max(1.594, 0)) )/ 2 )
=-43.78/( ( 142.618 + 142.665 )/ 2 )
=-43.78/142.6415
=-30.69 %

Note: The EBIT data used here is four times the quarterly (Dec. 2023) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Instil Bio  (NAS:TIL) ROC (Joel Greenblatt) % Explanation

The way Joel Greenblatt defines Return on Capital is a more accurate measure of how efficiently the company generates returns onthe capital actually invested in the business. EBIT is used instead of net income because the tax and interest payment may be affected by factors other than the core business operation. Intangible assets are not included in the calculation because they don't need to be replaced.

Joel Greenblatt uses his definition of Return on Capital and Earnings Yield (Joel Greenblatt) % to rank companies.


Instil Bio ROC (Joel Greenblatt) % Related Terms

Thank you for viewing the detailed overview of Instil Bio's ROC (Joel Greenblatt) % provided by GuruFocus.com. Please click on the following links to see related term pages.


Instil Bio (Instil Bio) Business Description

Traded in Other Exchanges
N/A
Address
3963 Maple Avenue, Suite 350, Dallas, TX, USA, 75219
Instil Bio Inc is a clinical-stage biopharmaceutical company focused on developing an innovative cell therapy pipeline of autologous tumor infiltrating lymphocyte, or TIL, therapies for the treatment of patients with cancer. It is also engaged in developing a novel class of genetically engineered TIL therapies using our Co-Stimulatory Antigen Receptor, or CoStAR, platform. The company's lead product candidate, ITIL-168, is an autologous TIL therapy that it is initially developing for the treatment of PD-1-inhibitor relapsed or refractory advanced melanoma.
Executives
Timothy L. Moore officer: Chief Operating Officer C/O KITE PHARMA, INC., 2225 COLORADO AVE., SANTA MONICA CA 90404
Sumita Ray officer: Chief Legal and Admin Officer C/O PHARMACYCLICS, INC., 995 EAST ARQUES AVENUE, SUNNYVALE CA 94085
Nimish P Shah director 7 BRYANT PARK, 23RD FLOOR, NEW YORK CITY NY 10018
Jack Nielsen director, 10 percent owner C/O AKEBIA THERAPEUTICS, INC., 245 FIRST STREET, SUITE 1100, CAMBRIDGE MA 02142
Vivo Capital Fund Ix, L.p. 10 percent owner 192 LYTTON AVENUE, PALO ALTO CA 94301
Mcgaughy R Kent Jr director 500 CRESCENT COURT, SUITE 250, DALLAS TX 75201
Curative Ventures V Llc 10 percent owner 3963 MAPLE AVENUE, SUITE 390, DALLAS TX 75219
Bronson Crouch director, 10 percent owner, officer: CEO and Chairman C/O INSTIL BIO, INC., 3963 MAPLE AVENUE, SUITE 350, DALLAS TX 75219
Vivo Capital Ix, Llc 10 percent owner 192 LYTTON AVENUE, PALO ALTO CA 94301
Sandeep Laumas officer: CFO and CBO 8480 HONEYCUTT RD, SUITE 200, RALEIGH NC 27615
Neil W Gibson director C/O REGULUS THERAPEUTICS INC., 3545 JOHN HOPKINS COURT SUITE 210, SAN DIEGO CA 92121
Gwendolyn Binder director C/O CABALETTA BIO, INC., 2929 ARCH STREET, SUITE 600, PHILADELPHIA PA 19104
Zachary Roberts officer: Chief Medical Officer C/O INSTIL BIO, INC., 3963 MAPLE AVENUE, SUITE 350, DALLAS TX 75219
George Matcham director C/O INSTIL BIO, INC., 3963 MAPLE AVENUE, SUITE 350, DALLAS TX 75219
Vijay Chiruvolu officer: Chief Technical Officer C/O TURNSTONE BIOLOGICS CORP., 9310 ATHENA CIRCLE, SUITE 300, LA JOLLA CA 92037

Instil Bio (Instil Bio) Headlines

From GuruFocus